CROSS-REFERENCED TO RELATED APPLICATIONS

[0001] The present patent application claims the priority benefit of U.S. provisional patent number 62/817,432 filed March 12, 2019, the disclosure of which is incorporated by reference herein.

BACKGROUND OF THE INVENTION

1. Field of the Disclosure

[0002] The present disclosure is generally related to cannabinoid transdermal patches. More particularly, this invention relates to selecting cannabinoid transdermal patches based on a specific ailment.

2. Description of the Related Art

[0003] Cannabis contains a wide range of components, including cannabinoids, and various terpenes and terpenoids. The use of cannabinoids and other cannabis components to treat medical injuries and illnesses is now widely accepted. Many studies have shown the benefits of using cannabinoids to relieve symptoms of a large number of ailments, including pain, nausea, inflammation, gastrointestinal disorders, depression, anxiety, PTSD, convulsions, seizures, muscle spasm, fatigue, insomnia, appetite loss, glaucoma, etc. Specific illnesses may require different specific cannabinoids at different dosages, or different mixtures and ratios of cannabinoids or different mixtures and ratios of cannabinoids with other cannabis components. Treatment may also be different depending on the demographics of the user (e.g., age, sex, height, weight, life habits, etc.).

[0004] Administering cannabinoids transdermally via a transdermal patch avoids gastrointestinal (first-pass) metabolism associated with oral delivery. This may provide a more measured delivery dosage. BRIEF DESCRIPTIONS OF THE DRAWINGS

[0005] FIG. 1 illustrates an exemplary network environment in which a system for selecting cannabinoid dosage for transdermal patches may be implemented.

[0006] FIG. 2 illustrates an exemplary cannabinoid treatment database.

[0007] FIG. 3 is a flowchart illustrating an exemplary method for providing condition-based cannabinoid dosage for transdermal patches.

[0008] FIG. 4 illustrates an exemplary demographics database.

[0009] FIG. 5 is a flowchart illustrating an exemplary method for adjusting cannabinoid dosage for transdermal patches.

DETAILED DESCRIPTION

[0010] Embodiments of the present invention indude a medical kit which contains transdermal patches and dosages of cannabis components that have different compositions for different ailments (e.g., injuries or illnesses). The system facilitates the selection of the proper composition and dosage for a specific ailment.

[0011] An embodiment of the present invention may be a system for selecting one or more cannabinoid transdermal patches. The user selects the right component and dose unit for the transdermal patch or patches for the selected ailment. The cannabinoid dose units or combination of dose units may be customized for specific ailments and demographic

information of the user. The dose may consist of a combination of one or more cannabinoids or other cannabis components.

[0012] The present invention enables the user to choose one or several cannabis transdermal patch dose units specific to individual ailments (e.g., injuries, illnesses and/or diseases) with a controlled dosage of cannabinoids and other components. In some embodiments, the user can treat specific ailments such as pain, nausea, inflammation, gastrointestinal disorders, depression, anxiety, PTSD, convulsions, seizures, muscle spasm, fatigue, insomnia, appetite loss, glaucoma.

[0013] FIG. 1 illustrates an exemplary network environment in which a system for selecting cannabinoid dosage for transdermal patches may be implemented. As illustrated, the network environment may include a treatment network 102, a transdermal patch kit 112, and a mobile device 114.

[0014] The treatment network 102 may include cannabinoid treatment database 104, a cannabinoid treatment information module 106, an application programming interface ("API") 108, and a demographics database 110. The treatment network 102 provides for cannabinoid- based treatments for specific ailments and the specific cannabinoid or cannabinoid mixture dosage for each specific ailment. The cannabinoid treatment database 104 is a database that contains the cannabinoid profile for each cannabinoid transdermal patch treatment for a specific ailment. The cannabinoid treatment database 104 correlates the specific ailment to the specific cannabinoid treatment. The cannabinoid treatment may be the specific cannabinoid or cannabinoid mixture dosage. In an embodiment, the cannabinoid treatment may be a transdermal patch or combination of transdermal patches from a transdermal patch kit 112.

[0015] The cannabinoid treatment information module 106 is a software module that receives the selected ailment from the user through a transdermal patch mobile application 116 and retrieves the cannabinoid treatment profile information for the selected ailment(s) from the cannabinoid treatment database 104. The cannabinoid treatment information module 106 then sends the data to an adjustment module 120 on the user's mobile device 114. For example, a user may select nausea and vomiting in a user interface 118 of the mobile device 114 as the ailment they want to treat. The cannabinoid treatment information module 106 would open the database 104 and reach the appropriate cannabinoid treatment for the specific ailment (e.g., 10 mg THC).

[0016] The API 108 is an interface that allows the treatment network to communicate with the mobile device 114. The demographics database 110 is a database that contains the adjusted concentration of a cannabinoid treatment based on personal demographics (e.g., age, sex, height, weight) and life habits (e.g., alcohol use, tobacco use, etc.).

[0017] The transdermal patch kit 112 contains multiple transdermal patches of different shapes and sizes containing different cannabinoids, mixtures of cannabinoids, and/or mixtures of cannabinoids and other cannabis components at different dosages and a code to download the transdermal patch mobile application 116. The transdermal patch kit may contain a plurality of transdermal patches containing different dosages of individual cannabinoids, or mixtures of cannabinoids at different ratios, or mixtures of cannabinoids and other cannabis components at different ratios. The transdermal patches contained in the transdermal patch kit may contain any type of cannabinoid, including but not limited to tetrahydrocannabinol (THC), cannabidiol (CBD), tetrahydrocannabivarin (THCv), cannabinol (CBN), cannabichromene (CBC), or the cannabinoid acids, which have a carboxylic add substituent, such as THCA and CBD A. The transdermal patches in the transdermal patch kit may be specifically formulated with any exdpients, carrier agents or permeation agents known in the art to improve penetration of the dermal barrier and delivery of the components to the bloodstream. In one embodiment, the transdermal patches contained in the transdermal patch kit may be color coded by type of cannabinoid or dosage.

[0018] The mobile device 114 is a user device (e.g., laptop, smartphone, tablet, smart watch, etc.) that receives and sends information from/to the extract information module 106 in the treatment network 102 via its communication hardware and the user input. The mobile device 114 contains the transdermal patch mobile application 116, the user interface 118, and the adjustment module 120.

[0019] The transdermal patch mobile application 116 is a mobile application that allows the user to select the specific ailment they want to treat and adjust the suggested dose/concentration received from the cannabinoid treatment information module 106 in the treatment network 102 to their individual use (e.g. weight, age, etc.). For example, the user may be asked a series of questions (e.g., questions regarding age, sex, height, weight, alcohol usage per week, smoker, recreation use of cannabis, and medicinal use of cannabis). Based on the user's answers, the user may receive a recommended transdermal patch or combination of transdermal patches from the transdermal patch kit.

[0020] The user interface(s) 118 may accept inputs from users or provide outputs to the users or perform both actions. In one embodiment, the user can interact with the interface(s) using one or more user-interactive objects and devices. The user-interactive objects and devices may comprise user input buttons, switches, knobs, levers, keys, trackballs, touchpads, cameras, microphones, motion sensors, heat sensors, inertial sensors, touch sensors, or a combination of the above. Further, the interface(s) 118 may either be implemented as a command line interface ("CLI"), a graphical user interface ("GUI"), a voice interface, or a web-based user-interface.

[0021] The adjustment module 120 is software that calculates the adjusted dosage concentration (e.g., number or combination of transdermal patches from the transdermal patch kit) the user should use based on personal parameters. In addition, the adjustment module 120 notifies the user of how to adjust the dosage of a specific treatment via a combination of transdermal patches to apply from the transdermal patch kit.

[0022] FIG. 2 illustrates an exemplary cannabinoid treatment database (e.g., cannabinoid treatment database 104). As illustrated, the cannabinoid treatment database 104 may store information about the specific cannabinoids or mixtures of cannabinoids or mixtures of cannabinoids and other cannabis components used to treat different ailments. The cannabinoid treatment database 104 may be populated and updated by various clinical trials and studies.

[0023] FIG. 3 is a flowchart illustrating an exemplary method for providing condition-based cannabinoid dosage for transdermal patches. Such method may be based on execution of cannabinoid treatment information module 106. One skilled in the art will appreciate that, for this and other processes and methods disclosed herein, the functions performed in the processes and methods may be implemented in differing order. Furthermore, the outlined steps and operations are only provided as examples, and some of the steps and operations may be optional, combined into fewer steps and operations, or expanded into additional steps and operations without detracting from the essence of the disclosed embodiments.

[0024] The method of FIG. 3 may begin with the cannabinoid treatment information module 106 receiving the user selection for the specific ailment from the user mobile device 114 at step 300. The cannabinoid treatment information module 106 then opens the cannabinoid treatment database 104 at step 302. The cannabinoid treatment information module 106 retrieves the specific cannabinoids, combination of cannabinoids, ratio of cannabinoids, combination and ratios of cannabinoids and other cannabis components and dosages for the specific ailment to be treated at step 304. For example, the user may select inflammation and pain in the user interface of the mobile device as the ailment they want to treat. The cannabinoid information module 106 would open the cannabinoid treatment database 104 at step 302 and retrieve the appropriate cannabinoid treatment for inflammation and pain for the specific ailment (e.g., a mixture of cannabichromene (CBC) 2 mg with THC:CBD 1:1 ratio 10 mg). The cannabinoid treatment information module 106 sends this information to the adjustment module 129 in the mobile application at step 306.

[0025] FIG. 4 illustrates an exemplary demographics database (e.g., demographics database 110). As illustrated, the demographics database 110 may store the adjusted concentration of a cannabis extract based on personal demographics (e.g., the user's age, sex, height, weight, etc.) and life habits (e.g., alcohol use, tobacco use, etc.). [0026] FIG. 5 is a flowchart illustrating an exemplary method for adjusting cannabinoid dosage for transdermal patches. Such method may be based on execution of adjustment module 120.

[0027] The method of FIG. 5 may begin with the adjustment module 120 receiving the cannabinoid and suggested concentration for the specific ailment from the cannabinoid treatment information module 106 at step 400. The adjustment module 120 asks a series of questions about the personal demographics (e.g., age, sex, height, weight, and habits of drinking and smoking, etc.) of the user by means of the user interface 118 of the mobile device 114 at step 402. The adjustment module 120 opens the demographics database 110 stored on the treatment network 102 at step 404. The adjustment module 120 retrieves an adjusted cannabinoid treatment for the specific ailment and the specific demographics of the user at step 406. The adjustment module 120 calculates the adjusted cannabinoid treatment dosage at step 408 and calculates how to select the specific type and number of transdermal patches from the transdermal patch kit 112 based on the adjusted cannabinoid treatment dosage. The adjustment module recommends a cannabinoid treatment based on the adjusted cannabinoid treatment dosage and instructs the user on how to select the specific type and number of transdermal patches from the transdermal patch kit 112 to the user by means of the user interface 118 of the mobile device 114 at step 410.

[0028] The foregoing detailed description of the technology has been presented for purposes of illustration and description. It is not intended to be exhaustive or to limit the technology to the precise form disclosed. Many modifications and variations are possible in light of the above teaching. The described embodiments were chosen in order to best explain the principles of the technology, its practical application, and to enable others skilled in the art to utilize the technology in various embodiments and with various modifications are suited to the particular use contemplated.